Achieving high-spatial-resolution in ambient mass spectrometry imaging (MSI) is critical in accurately characterizing the spatial distribution of biomolecules. Ambient MSI enables in situ mapping spatial heterogeneity of metabolites under ambient conditions, facilitating molecular imaging from multicellular structure down to subcellular level. In this review, we first summarized the strategies developed to enhance spatial resolution in ambient MSI, including technological innovations, advances...

Free-radical photopolymerization enables the spatial and temporal customization of the viscoelastic properties of polymers for multifunctional designs. Adjusting light intensity and exposure time can be used to control the kinetics of photopolymerization and, therefore, the nonuniformity in the viscoelastic properties of the polymerized material. Additionally, polymerization that occurs in the dark after partial radical photopolymerization must be taken into account to accurately assess the...

BACKGROUND: Hamstring tendon autograft remains a popular graft choice for anterior cruciate ligament (ACL) reconstruction because of its favorable biomechanical properties, lower donor-site morbidity, and comparable functional outcomes to bone-patellar tendon-bone (BPTB) autograft^(1-5). However, variability in hamstring graft size and length remains a challenge, particularly in female or short-statured patients⁷. Smaller graft diameters are consistently associated with increased failure and...

Ecological momentary assessments (EMAs) effectively measure dynamic changes in constructs such as affect. Accurate assessment of affect variability may depend on study design characteristics. While EMAs delivered at random intervals are typically considered superior for capturing variability compared to EMAs delivered at set timepoints, there have been few experimental comparisons of these assessment methodologies. The present study used data from a nationwide factorial experiment to identify...

CONCLUSIONS: In patients with IPF, treatment with inhaled treprostinil led to a smaller decline in FVC and fewer clinical-worsening events than placebo over the course of 52 weeks. (Funded by United Therapeutics; TETON-1 ClinicalTrials.gov number, NCT04708782.).